Key Takeaways
- Estrogen-only menopausal hormone therapy is associated with a lower risk of Alzheimer's pathology and dementia in women.
- The study analyzed data from over 21,000 participants, showing noteworthy brain health benefits tied to hormone therapy.
- Findings challenge previous notions linking hormone therapy to heightened dementia risks.
A recent study from Stanford University provides illuminating evidence that women utilizing estrogen-only hormone therapy may experience a reduced risk of developing Alzheimer's-related brain changes and dementia. The findings, published on August 12 in the journal Neurology, delve into the post-mortem analyses of 21,462 participants, comparing 258 women who reported using estrogen-only menopausal hormone therapy (MHT) with approximately 2,701 women who did not.
The research team focused on typical Alzheimer’s pathology markers, including amyloid plaques and neurofibrillary tangles. These two changes are recognized hallmarks of the disease. Remarkably, the women who underwent estrogen-only therapy were found to possess a 35% lower likelihood of developing Alzheimer's pathology and a 39% reduced risk of dementia throughout their lifetime.
Among living participants, those engaging in estrogen-only therapy demonstrated improved cognitive performance and greater abilities to function independently, with biomarkers in blood and cerebrospinal fluid reinforcing these findings. The average age of participants in the study was around 70 years.
Recent research has suggested that the advantages of menopausal hormone therapy escalate when initiated during or shortly after menopause. Notably, the women in the cohort typically began their treatment later, potentially downplaying the benefits of beginning therapy at an earlier stage.
The findings appear to oppose earlier research that associated hormone therapy with an increased risk of dementia. Jennifer Bruno, PhD, one of the study's authors, remarked, "Estrogen has well-documented neuroprotective effects in animal models and plays a vital role in shifting amyloid toward a non-amyloidogenic pathway while promoting tau dephosphorylation—critical factors associated with Alzheimer’s disease pathology."
Bruno further highlighted that estrogen aids in reducing neuroinflammation and maintaining the integrity of the blood-brain barrier, contributing to the lower observed Alzheimer’s pathology in users of estrogen-only therapy.
Despite the promising results, researchers acknowledged some limitations of the study. Being purely observational, it can only establish associations and cannot conclusively prove that hormone therapy reduces Alzheimer’s risk. Hadi Hosseini, PhD, the senior author, stressed that differences in baseline health status among users and non-users may not be fully captured in the data.
Although these findings do not alter contemporary clinical guidelines, they emphasize a significant need for well-structured clinical trials to further investigate the potential cognitive benefits of menopausal hormone therapy. Bruno concluded, "These outcomes provide substantial, first-of-their-kind pathological evidence that demands further study, but do not serve as a basis for altering current MHT practices."
Why This Matters
This research underscores the evolving conversation around menopausal hormone therapy and its implications for women's cognitive health. As Alzheimer’s disease remains a leading cause of dementia, particularly among women, further exploration into hormone therapy could reveal its potential as a preventive measure.